Related Experiment Videos
Conditional hepatocarcinogenesis in mice expressing SV 40 early sequences
Dan-Qing Lou1, Thierry Molina, Myriam Bennoun
1Département GDPM, Institut Cochin, INSERM U-567, CNRS UMR 8104, Université Paris 5, 24 rue du Faubourg Saint-Jacques, 75014 Paris, France.
Cancer Letters
|September 15, 2005
Summary
Researchers developed a new mouse model that accurately replicates human liver cancer development. This model allows for the study of early cancer stages and the evaluation of potential new therapies for hepatocellular carcinoma.
Area of Science:
- Hepatology
- Oncology
- Transgenic animal models
Background:
- Sporadic hepatocarcinoma (liver cancer) arises in vivo.
- Existing models may not fully recapitulate the in vivo setting for liver cancer development.
Purpose of the Study:
- To establish a novel transgenic mouse model that mimics sporadic hepatocarcinoma.
- To enable investigation of early preneoplastic processes in the liver.
- To identify potential therapeutic targets for liver cancer.
Main Methods:
- Developed a transgenic mouse model with regulatable SV40 early sequences under hepatic control (human antithrombin III gene regulatory sequences).
- Activated oncogenic sequences using adenoviral Cre recombinase or liver-specific, tamoxifen-inducible Cre expression.
- Induced hepatocellular carcinoma (HCC) through controlled oncogene activation.
Main Results:
- Successfully generated a mouse model that develops hepatocellular carcinoma.
- Demonstrated that both adenoviral and inducible Cre systems effectively activated oncogenes in the liver.
- The model closely mimics the in vivo conditions of sporadic liver cancer.
Conclusions:
- The developed transgenic mouse model is a valuable tool for studying hepatocarcinogenesis.
- This model facilitates research into the preneoplastic stages of liver cancer.
- It offers a platform for preclinical testing of novel therapeutic strategies for HCC.